Stockscreener 앱 받기
7.25
1.36%
-0.10
시간 외 거래:
7.25
Sage Therapeutics Inc 주식(SAGE)의 최신 뉴스
Key deals this week: Molson Coors Beverage, Emerson Electric, Sage Therapeutics and more - Seeking Alpha
FY2025 Earnings Estimate for SAGE Issued By Leerink Partnrs - MarketBeat
Deal Dispatch: Sage And Silvus Are Up For Sale, MrBeast Secures $20B For TikTok - Benzinga
Vanguard Group Inc Reduces Stake in Sage Therapeutics Inc - GuruFocus.com
Bronstein, Gewirtz & Grossman, LLC Encourages Sage Therapeutics, Inc. (SAGE) Investors to Inquire about Securities Investigation - Markets Insider
SAGE Rejects Biogen's Offer to Buy Remaining Stake, Stock Up - MSN
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates - MSN
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen, Cytokinetics and Akero Therapeutics - Yahoo Finance
SAGESage Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 - Business Wire
Postpartum Depression Market Expected to rise, 2034 | Pfizer, Sage Therapeutics, Lipocine Inc, Eli Lilly and Company, GSK, Canopie, Talkspace, expected to drive market - Barchart
Postpartum Depression Market Expected to rise, 2034 | Pfizer, - openPR
Sage rejects Biogen takeover and launches review - pharmaphorum
Sage Spurns Biogen, Turns Attention To Strategic Review - News & Insights
Sage Therapeutics rejects Biogen bid, starts strategic review - MSN
Sage rejects Biogen’s buyout offer, but says it's open to deals - The Business Journals
Sage Therapeutics shares rise amid strategic review - Investing.com
Sage rejects Biogen's $469 million takeover offer, says offer undervalues company - Reuters
Sage Therapeutics Turns Down Biogen's Unsuitable OfferNews and Statistics - IndexBox, Inc.
Sage Therapeutics rejects Biogen bid, starts strategic review (SAGE:NASDAQ) - Seeking Alpha
Sage Therapeutics shares rise amid strategic review By Investing.com - Investing.com South Africa
Sage rejects Biogen's takeover offer, to explore strategic alternatives -January 27, 2025 at 09:28 am EST - Marketscreener.com
Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives -January 27, 2025 at 09:20 am EST - Marketscreener.com
FY2024 EPS Estimates for Sage Therapeutics Lifted by Wedbush - MarketBeat
Sage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Assenagon Asset Management S.A. - MarketBeat
JPMorgan Chase & Co. Decreases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE) - MarketBeat
Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm - GlobeNewswire Inc.
FY2029 Earnings Estimate for SAGE Issued By Wedbush - MarketBeat
Sage Therapeutics Looks Like A 'Strong Buy' With Zurzuvae's Potential & Biogen's Bid - Seeking Alpha
How To Trade (SAGE) - Stock Traders Daily
Sage Sues Partner Biogen After Unsolicited Takeover Offer - BioSpace
Sage sues Biogen after unsolicited takeover bid - pharmaphorum
Sage Therapeutics Stock Soars as Biogen Makes Unsolicited Takeover Bid - MSN
Sage sues Biogen in wake of $469M buyout offer: report (BIIB:NASDAQ) - Seeking Alpha
Biogen Sued by Neuroscience Company Sage After Buyout Offer (1) - Bloomberg Law
BB Biotech AG Significantly Reduces Stake in Sage Therapeutics I - GuruFocus.com
Biogen Offers to Buy Remaining Stake in Sage Therapeutics - MSN
Sage Therapeutics, Inc. (NASDAQ:SAGE) Short Interest Down 24.6% in December - MarketBeat
Sage Therapeutics: Biogen's Unsolicited Bid Is Best Step Forward For Shareholders - Seeking Alpha
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen - MSN
Sage Therapeutics (SAGE) Moves 35.1% Higher: Will This Strength Last? - MSN
Sage Therapeutics Stock Eyes Best Day In 5 Years On Biogen’s Unsolicited Bid: Retail Piles In - MSN
Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist - Yahoo Finance
Biogen proposes acquisition of partner Sage Therapeutics - MSN
Biogen CEO sees no burning need for more acquisitions - Reuters
Biogen’s ‘cold and calculated’ offer to buy Sage receives a mixed reaction on Wall Street - BioPharma Dive
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Sage Therapeutics, Inc. (SAGE) and Encourages Shareholders to Learn More About the Investigation - AccessWire
Biogen Bid For Sage Therapeutics Could Strengthen Neurology Strategy: Analysts - Benzinga
Crude Oil Surges 3%; Abercrombie & Fitch Shares Plunge - Benzinga
Sage Therapeutics shares surge on unsolicited takeover bid from Biogen - Proactive Investors USA
Sage Therapeutics Stock Headed for Best Day in 5 Years - Schaeffers Research
3.95%
2.39%
자본화:
|
볼륨(24시간):